

GOLIMUMAB

2014

PURSUIT-SC

RCT phase 2&3/ Golimumab vs placebo/ Mod-severe UC/ Induction of remission

Conclusion:

Treatment with SC golimumab induces clinical response, remission, and mucosal healing, and increases quality of life in larger percentages of patients with active UC than placebo.

2014

PURSUIT-M

RCT/ Golimumab vs placebo/ Mod-severe UC/ Maintenance

Conclusion:

Golimumab maintained clinical response through w54 in patients who responded to induction therapy and had mod-severe UC.

2015

PURSUIT-IV

RCT/ Golimumab IV vs placebo/ Mod-severe UC/ Induction

Conclusion:

Efficacy with single-dose golimumab IV induction was lower than expected and less than observed in the SC induction study. No new safety findings were observed.